Immediate Impact
2 from Science/Nature 61 standout
Citing Papers
Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
2023 Standout
Works of D. Chu being referenced
Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)
2009
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| D. Chu | 426 | 356 | 125 | 6 | 502 | |
| Adel Zaatar | 368 | 324 | 124 | 9 | 467 | |
| She-Juan An | 361 | 278 | 137 | 7 | 447 | |
| Norihiro Yamaguchi | 299 | 227 | 150 | 7 | 433 | |
| Philip Tracy | 467 | 349 | 208 | 6 | 526 | |
| James Stevens | 423 | 323 | 167 | 6 | 526 | |
| Eric D. Mininberg | 304 | 340 | 194 | 6 | 489 | |
| L A Speicher | 288 | 291 | 177 | 8 | 532 | |
| F Bianchi | 359 | 293 | 89 | 9 | 429 | |
| Kalyanee Viraswami-Appanna | 397 | 354 | 192 | 9 | 547 | |
| Joseph Burke | 481 | 387 | 97 | 7 | 551 |
All Works
Login with ORCID to disown or claim papers
Loading papers...